Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain

Epalza, Cristina; Prieto-Tato, Luis; Pino, Rosa; Escartín-Paredes, Paula; Leoz, Inés; Grasa, Carlos; Vivanco-Allende, Ana; Rivière, Jacques G.; Carrasco-Colom, Jaume; Villate, Olatz; Fumadó, Victòria; Hermoso-Ibañez, Concepción; Herrero, Blanca; Aguilera‐Alonso, David; Tagarro, Alfredo; Moraleda, Cinta

doi:10.1093/jpids/piac076

Cited by 5 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hoste et al's international study of 273 children post-PIMS-TS also showed no concerning post-vaccination symptoms, with a single case of Bell's paralysis resolving without complications [20]. A Spanish study involving 32 post-PIMS-TS patients vaccinated without severe adverse reactions or PIMS-TS recurrence further supports the safety of vaccination [21]. Enthralling data from MAS/sJIA and Vaccination Working Parties of the Pediatric Rheumatology European Society described the results of a survey involving respondents from over 60 countries who provide vaccinations to children with a history of PIMS-TS.…”

Section: Vaccination Safety In Children Who Have Undergone Pims-tsmentioning

confidence: 89%

Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review

Opoka-Winiarska,

Morawska-Michalska,

Mertowska

et al. 2024

Vaccines

View full text Add to dashboard Cite

Pediatric inflammatory, multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS), also known as a multisystem inflammatory syndrome in children (MIS-C), is diagnosed in children who develop an inadequate inflammatory response after exposure to the SARS-CoV-2 virus. The pathogenesis of the abnormal response of the immune system to a previous SARS-COV-2 infection has not been explained. Similarly, the safety and effectiveness of COVID-19 vaccinations in this group of patients have become the subject of clinical discussion. Presenting experiences from many centers aims to answer this question. We present 4 cases of patients who suffered from PIMS-TS. Three of them were safely vaccinated against COVID-19 after illness. One patient developed PIMS-TS temporarily associated with COVID-19 vaccination. We also collected and discussed data from other centers.

show abstract

Section: Vaccination Safety In Children Who Have Undergone Pims-tsmentioning

confidence: 89%

Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review

Opoka-Winiarska,

Morawska-Michalska,

Mertowska

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…The apprehensions included fears regarding potential side effects and the perception that the vaccine was not well researched, similar to other studies. 6 , 20 External factors and the environment also played a role in parents’ decision-making, including advice from family members or doctors. Indeed, other studies reported that pediatricians were among the most trusted source of information for COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the vaccine was well tolerated in MIS-C children and was not associated to any relapse of MIS-C episode. 6 , 7 In other countries, the vaccination strategy for children post-MIS-C was debated. In France, for instance, SARS-CoV-2 vaccination was initially contraindicated in this population but their position was revised in February 2022 to recommend vaccination.…”

mentioning

confidence: 99%

COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children

Blanchard-Rohner,

Sanchez,

Andre

et al. 2024

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT 04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.

show abstract

“… 11 Small series of 15 and 32 patients reported no serious adverse events after vaccination. 12 , 13 An international survey of health care professionals from 32 countries collected information from 273 vaccinated patients with prior MIS-C and reported no cases of MIS-C relapse. 14 However, that study was limited by a lack of individual patient data.…”

Section: Discussionmentioning

confidence: 99%

Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children

et al. 2023

View full text Add to dashboard Cite

ImportanceData are limited regarding adverse reactions after COVID-19 vaccination in patients with a history of multisystem inflammatory syndrome in children (MIS-C). The lack of vaccine safety data in this unique population may cause hesitancy and concern for many families and health care professionals.ObjectiveTo describe adverse reactions following COVID-19 vaccination in patients with a history of MIS-C.Design, Setting, and ParticipantsIn this multicenter cross-sectional study including 22 North American centers participating in a National Heart, Lung, and Blood Institute, National Institutes of Health–sponsored study, Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children (MUSIC), patients with a prior diagnosis of MIS-C who were eligible for COVID-19 vaccination (age ≥5 years; ≥90 days after MIS-C diagnosis) were surveyed between December 13, 2021, and February 18, 2022, regarding COVID-19 vaccination status and adverse reactions.ExposuresCOVID-19 vaccination after MIS-C diagnosis.Main Outcomes and MeasuresThe main outcome was adverse reactions following COVID-19 vaccination. Comparisons were made using the Wilcoxon rank sum test for continuous variables and the χ2 or Fisher exact test for categorical variables.ResultsOf 385 vaccine-eligible patients who were surveyed, 185 (48.1%) received at least 1 vaccine dose; 136 of the vaccinated patients (73.5%) were male, and the median age was 12.2 years (IQR, 9.5-14.7 years). Among vaccinated patients, 1 (0.5%) identified as American Indian/Alaska Native, non-Hispanic; 9 (4.9%) as Asian, non-Hispanic; 45 (24.3%) as Black, non-Hispanic; 59 (31.9%) as Hispanic or Latino; 53 (28.6%) as White, non-Hispanic; 2 (1.1%) as multiracial, non-Hispanic; and 2 (1.1%) as other, non-Hispanic; 14 (7.6%) had unknown or undeclared race and ethnicity. The median time from MIS-C diagnosis to first vaccine dose was 9.0 months (IQR, 5.1-11.9 months); 31 patients (16.8%) received 1 dose, 142 (76.8%) received 2 doses, and 12 (6.5%) received 3 doses. Almost all patients received the BNT162b2 vaccine (347 of 351 vaccine doses [98.9%]). Minor adverse reactions were observed in 90 patients (48.6%) and were most often arm soreness (62 patients [33.5%]) and/or fatigue (32 [17.3%]). In 32 patients (17.3%), adverse reactions were treated with medications, most commonly acetaminophen (21 patients [11.4%]) or ibuprofen (11 [5.9%]). Four patients (2.2%) sought medical evaluation, but none required testing or hospitalization. There were no patients with any serious adverse events, including myocarditis or recurrence of MIS-C.Conclusions and RelevanceIn this cross-sectional study of patients with a history of MIS-C, no serious adverse events were reported after COVID-19 vaccination. These findings suggest that the safety profile of COVID-19 vaccination administered at least 90 days following MIS-C diagnosis appears to be similar to that in the general population.

show abstract

Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain

Cited by 5 publications

References 2 publications

Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review

Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review

COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children

Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children

Contact Info

Product

Resources

About